| human | Q5 |
| P496 | ORCID iD | 0000-0002-1670-6513 |
| P106 | occupation | researcher | Q1650915 |
| Q99208905 | 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial |
| Q50174880 | 8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms |
| Q41197125 | A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients |
| Q90715370 | A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia |
| Q89882474 | A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia |
| Q91660743 | A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure |
| Q90997833 | A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis |
| Q91302761 | A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis |
| Q44041367 | A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia |
| Q35132525 | A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia |
| Q48309941 | A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. |
| Q50330287 | A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase |
| Q46744333 | A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia |
| Q38372745 | A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN. |
| Q38431987 | A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine |
| Q33415505 | Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients |
| Q38235764 | Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation |
| Q97540090 | Acute promyelocytic leukemia (APL) with an IRF2BP2-RARA fusion transcript: an aggressive APL variant |
| Q53100553 | Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report. |
| Q87137879 | Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia |
| Q40261354 | An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes |
| Q46058919 | Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN. |
| Q36094702 | Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy |
| Q38780706 | Analysis of the Use and Impact of Twitter During American Society of Clinical Oncology Annual Meetings From 2011 to 2016: Focus on Advanced Metrics and User Trends |
| Q98281632 | Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: A novel finding and possible diagnostic pitfall |
| Q98719933 | Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm |
| Q64992991 | Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. |
| Q97594780 | Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia |
| Q33915887 | Atypical chronic lymphocytic leukemia with polyglandular autoimmune endocrinopathy type II: a complex profile |
| Q34550540 | Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). |
| Q37693266 | BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells |
| Q104060007 | BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study |
| Q33914289 | Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia |
| Q58594797 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community |
| Q39093595 | Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. |
| Q101453745 | Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms |
| Q37715074 | Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias |
| Q101453611 | Cell cycle inhibitors for the treatment of acute myeloid leukemia: A review of phase 2 & 3 clinical trials |
| Q48305735 | Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach |
| Q34964597 | Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia |
| Q35688721 | Characteristics of Sweet Syndrome in patients with acute myeloid leukemia |
| Q91842389 | Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy |
| Q38250289 | Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literature |
| Q36876853 | Chronic myelomonocytic leukemia: Forefront of the field in 2015. |
| Q90986504 | Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial |
| Q88493206 | Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia |
| Q62383983 | Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies |
| Q101407113 | Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia |
| Q38636146 | Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience |
| Q36624496 | Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction |
| Q101059814 | Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations |
| Q35070447 | Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis |
| Q37235671 | Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia |
| Q48154329 | Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies |
| Q34276194 | Clinical significance of microcytosis in patients with primary myelofibrosis |
| Q41084893 | Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study |
| Q93207443 | Clinical value of event-free survival in acute myeloid leukemia |
| Q33949752 | Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia |
| Q98507252 | Clonal Evolution and Treatment Outcomes in Hematopoietic Neoplasms Arising in Patients with Germline RUNX1 mutations |
| Q47164848 | Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients |
| Q36751420 | Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study |
| Q90012163 | Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study |
| Q91371567 | Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis |
| Q36450182 | Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors |
| Q40858775 | DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia |
| Q47608483 | Disease-specific hashtags and the creation of Twitter medical communities in hematology and oncology |
| Q95561871 | Disseminated Saprochaete capitata (formerly known as Geotrichum capitatum and Blastoschizomyces capitatus) in a patient with acute myeloid leukemia |
| Q41349738 | Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia |
| Q93358783 | Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation |
| Q39164378 | Dorsal column myelopathy after intrathecal chemotherapy for leukemia |
| Q91514907 | Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm |
| Q43242156 | Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome |
| Q57482350 | Early detection of transformation to BPDCN in a patient with MDS |
| Q54979822 | Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. |
| Q33968372 | Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy |
| Q58577391 | Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study |
| Q102068473 | Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series |
| Q90237277 | Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms |
| Q47719432 | Erythroleukemia-historical perspectives and recent advances in diagnosis and management |
| Q27005996 | Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge |
| Q38219417 | Extramedullary acute myeloid leukemia: leukemic pleural effusion, case report and review of the literature |
| Q35048217 | FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era? |
| Q91767457 | Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN) |
| Q52719033 | Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. |
| Q40754724 | Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen |
| Q100302860 | First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations |
| Q90361192 | First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL) |
| Q89575171 | Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes |
| Q47339574 | Glioblastoma and acute myeloid leukemia: malignancies with striking similarities |
| Q51091822 | Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. |
| Q46294823 | Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma |
| Q46196747 | Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis |
| Q96693732 | Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial |
| Q92374811 | Ibrutinib and Venetoclax for First-Line Treatment of CLL |
| Q38301743 | Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia |
| Q96767821 | Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies |
| Q53083938 | Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement. |
| Q91520367 | Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm |
| Q36675052 | Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors |
| Q94477118 | Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin |
| Q94521079 | Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia |
| Q52668209 | Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. |
| Q35837709 | Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis |
| Q34772229 | Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience |
| Q93096897 | Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphobl |
| Q49905062 | Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study |
| Q48184250 | Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. |
| Q33943277 | Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia |
| Q37522963 | Is acute myeloid leukemia a liquid tumor? |
| Q90819616 | Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study |
| Q91965393 | Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia |
| Q52351939 | L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-induced Hyperbilirubinemia. |
| Q41870967 | Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents |
| Q60907709 | Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? |
| Q51738954 | Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. |
| Q90278177 | Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia |
| Q104103270 | Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience |
| Q99555199 | Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia |
| Q38791735 | Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia |
| Q40637708 | Mixed angioinvasive exserohilum and scedosporium infection in a patient with AML. |
| Q91807433 | Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation |
| Q34086334 | Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse |
| Q98950375 | Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3) |
| Q38859646 | Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents |
| Q97561890 | Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia |
| Q92360125 | Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors |
| Q88831310 | Ocular extramedullary myeloid leukaemia |
| Q34117308 | Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia |
| Q90040976 | Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies |
| Q33956085 | Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation |
| Q91596848 | Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens |
| Q96133852 | Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens |
| Q100502831 | Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML |
| Q64996202 | PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. |
| Q40525862 | PET-positive lymphadenopathy in CLL-Not always Richter transformation |
| Q36739522 | Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). |
| Q49978793 | Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms |
| Q90223575 | Patient with mixed-phenotype acute leukemia with CBFB rearrangement |
| Q33442613 | Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis |
| Q40085109 | Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents |
| Q97588379 | Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia |
| Q33420436 | Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia |
| Q35659879 | Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia |
| Q34146512 | Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia |
| Q96431804 | Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality |
| Q36909312 | Philadelphia-positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation |
| Q91876371 | Plesiomonas shigelloides gastroenteritis in a patient with chronic lymphocytic leukemia |
| Q36104098 | Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study |
| Q50902498 | Primary autoimmune myelofibrosis (MF) with high-grade peripheral T-cell lymphoma (PTCL) NOS. |
| Q34205736 | Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics |
| Q47659016 | Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors |
| Q93007724 | Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib |
| Q90734761 | Prognostic significance of hyperdiploidy in adult acute myeloid leukemia |
| Q37160073 | Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia |
| Q97649610 | Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era |
| Q50200720 | Questions on asparaginase-associated pancreatitis |
| Q47626725 | Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2 Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media-#MPNSM. |
| Q90448539 | Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm |
| Q35873909 | Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials |
| Q91703019 | Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes |
| Q95651971 | Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study |
| Q91694031 | Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN) |
| Q37216367 | Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis |
| Q92144663 | SMAC mimetics as potential cancer therapeutics in myeloid malignancies |
| Q33798909 | Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD |
| Q37074311 | Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study |
| Q40396529 | Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission |
| Q48144615 | Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis |
| Q38918870 | Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). |
| Q38594107 | Social Media and Myeloproliferative Neoplasms (MPN)--Focus on Twitter and the Development of a Disease-specific Community: #MPNSM. |
| Q38918874 | Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM. |
| Q101133643 | Social Media for Hematopathologists: Medical Practice Reinvented-#Hemepath |
| Q91920608 | Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia |
| Q35071654 | Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature |
| Q37153527 | Successful treatment of aplastic anemia-paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. |
| Q90481499 | Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia |
| Q60907880 | Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells |
| Q98208520 | Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years |
| Q36609771 | Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations |
| Q64297779 | Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia |
| Q44288796 | TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow |
| Q95926550 | Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm |
| Q92981032 | Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm |
| Q96609992 | The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia |
| Q89304860 | The co-occurrence of driver mutations in chronic myeloproliferative neoplasms |
| Q36007787 | The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. |
| Q47447844 | The use and impact of Twitter at medical conferences: Best practices and Twitter etiquette |
| Q35988523 | Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase |
| Q48179574 | Time to response and survival in hypomethylating agent-treated acute myeloid leukemia |
| Q92340994 | Topoisomerase II inhibitors in AML: past, present, and future |
| Q94555105 | Treating Leukemia in the Time of COVID-19 |
| Q102385324 | Treating Rosai-Dorfman disease and RAS-associated autoimmune leucoproliferative disorder with malignant transformation |
| Q36967029 | Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia |
| Q90460345 | Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial |
| Q60921654 | Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience |
| Q34343369 | Update on the biology and treatment options for hairy cell leukemia |
| Q90579239 | Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories |
| Q103829076 | Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality |
| Q42368321 | Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome |
Search more.